Rebecca Zacks
Rebecca is Xconomy's cofounder and executive editor. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University. Before becoming a journalist, she worked in the MIT lab of Nobel prizewinning neuroscientist Susumu Tonegawa.
Recent posts
-
…or really just one great one: Xconomy needs your help. We’re busy cranking out terrific tech and life sciences journalism and putting on stellar events across the six cities in our... Read more »
-
Regular visitors to Xconomy.com may have noticed that we did some redecorating over the weekend. Our new look and feel, courtesy of the crazy talented Rob Hunter of True Italic in... Read more »
-
This week New England’s life sciences community saw a couple of cool new companies emerge and a few potentially important new treatments reach key milestones.
—Boston-based Third Rock Ventures launched its newest startup with... Read more »
-
New England’s tech and life sciences companies have been inking deals all over the place this past week. First up, the big surprise…
—Cambridge, MA-based Endeca Technologies, an enterprise search and e-commerce... Read more »
-
Boston area radio listeners may have noticed something pretty cool on Friday morning: Xconomy’s on-air debut, during “Morning Edition” on WGBH’s 89.7. The Xconomy Report segment, which will be a regular feature... Read more »
-
A Cambridge, MA-based personal genomics company has raised $5 million from one investor in a round that could eventually total $20 million, according to a regulatory filing. Launched in 2007 by... Read more »
-
Sarah Schmid’s high school and mine were rivals, but I’m not holding it against her. In fact, having a home-grown Michigan journalist take up the reins of Xconomy Detroit is so exciting... Read more »
-
It’s easy to forget that Arlene Weintraub, Xconomy New York’s editor, has been running a one-woman show since joining us in April. Sure she’s had loads of help from her colleagues... Read more »
-
As if there weren’t already enough reasons to be looking forward to the June 16 Xconomy Summit on Innovation, Technology, and Entrepreneurship, today we’re adding a thin, shiny reason with HD... Read more »
-
It’s been less than a month since we launched Xconomy New York, and (to none of our surprise, really) we’re already finding there are more important innovation stories than even Arlene... Read more »
-
New England’s tech firms inked a bunch of deals this past week. Here are a few of them.
—Gemvara raised $15 million in a Series C funding round led by London-based Balderton Capital and joined... Read more »
-
New England’s biotech attorneys must be working overtime, if the week’s headlines are any indication.
—Cambridge, MA-based Alnylam (NASDAQ:ALNY) announced it had settled a long-standing legal dispute over the so-called Tuschl... Read more »
-
Software, tech, and stealth dominated the week’s deals news.
—TechStars Boston, the startup incubator program, raised about a quarter of a planned $2 million funding round. If completed, the round will reportedly support... Read more »
-
San Diego-based drug developer Meritage Pharma raised $2 million in a round of equity-based financing planned to total $5.5 million, an SEC filing indicates. Meritage is out to develop a treatment for a little-known... Read more »
-
Southeast Michigan, please be kind to Tom Lee. Thanks to some lame, opaque rues at an airline which shall remain nameless, the newest addition to the Xconomy team—who starts today as... Read more »
-
Dealmaking activity in New England’s tech and life sciences sectors continued at a blizzardy pace this week. Hold on to your hat…
—Marlborough, MA-based biofuels developer Qteros raised $22 million from new and... Read more »
-
I’ve got Frank Sinatra on endless mental replay today and I’ll tell you why: I’m looking for a stellar journalist to start spreading the news about innovation in New York, New York.... Read more »
-
2001 is off to a running start for dealmakers in New England’s tech and life sciences sectors, it seems.
—Cambridge, MA-based Genocea Biosciences pulled in a tidy $35 million in a Series B funding round. The... Read more »
-
New England’s life sciences companies headed into the holiday break with mostly good news.
—Syndax Pharmaceuticals reported results from a mid-stage clinical trial which suggest that its lead drug, entinostat, might help... Read more »
-
Lots of nice deals to report this week from New England’s tech and life sciences sectors.
—E-mail archiving provider Sonian indicated to the SEC that it had raised $4 million in an... Read more »
